NCT06034314

Oral Dronabinol-HIV

Investigation of the Effects of Cannabis on the Immune-genome in People With HIV

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to define the mechanisms of cannabis on the genome of people with HIV who use cannabis. The investigator aims to better understand the effect of Dronabinol on immune and inflammatory functions, and whether these changes are HIV-status dependent. This research may better inform public health policy regarding cannabis use. Depending on the results, additional studies may also build upon this research to develop more effective and specific treatments for cannabis use associated disorders.

Conditions

• HIV

Interventions

Type	Name	Description
DRUG	Dronabinol Capsules	Two 10 mg Dronabinol capsules will be administered orally, for a total of 20mg, on test day.

Timeline

• Start date: 2023-09-21
• Primary completion: 2026-10-01
• Completion: 2028-10-01
• First posted: 2023-09-13
• Last updated: 2025-11-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study